AMGN
AMGEN INC
NASDAQ · Healthcare · Drug Manufacturers - General · US
$469.05
+1.69%Year over year
Reported trailing growth
- Revenue
- +9.2%
- EBITDA
- +10.8%
- EBIT
- +54.6%
- EPS
- +31.7%
- Free cash flow
- -4.1%
- Operating cash flow
- +3.9%
Forward estimates
Based on analyst estimates
- Revenue
- +5.8%
- EBITDA
- +22.8%
- EPS
- +48.8%
Three-year CAGR
- Revenue
- +11.8%
- EBITDA
- +11.6%
- EBIT
- +3.7%
- Net income
- +5.6%
- EPS
- +5.6%
- Free cash flow
- -2.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026